Theratechnologies Inc T.TH

Trogarzo® Intramuscular Method refusal by FDA

[muslix1]

No news by Marsolais, close 3 months later...
''We will now assess our options regarding this application.” He said..
we abandon the intramuscular project or what
News please

[Trogarzon]

They said that IM was not being pursued already.  Never really understood the added value since IV push was just approved and much better than the original one.  Trogarzo is tending sideways to down and Egrifta still growing a bit.  It pays the interest bills until they can raise more on the back of the pipeline promise eventually.  Otherwise it's the specialty pharma

[SPCEO1]

I suspect you were thinking about the F8 formulation of Egrifta as we were supposed to hear something about it being resubmitted but that has not happened yet. While such things always seem to take longer than the company suggests it will, the delay does leave some reason to be concerned about it. Unless the company chooses to say something sooner, the next time we would get an update is mid-July.

[Trogarzon]

Exciting ain't it... woohoo 40 cents summer and a ongoing concern. Enjoy the weather and tahnk you for your patience, all 30 years of it.

[palinc2000]

April 10 2024 CC What more do you need? Finally, I want to touch on the Intramuscular Administration of the Trogarzo maintenance dose. The refusal to file letter received from the FDA in February indicates that it would require the conduct of a new study to pursue the registration of the IM method administration. Given the cost of the study and the evolving competitive landscape, we have